基于脑脊液和血液样本的乳腺癌脑转移相关耐药基因突变的鉴定及功能分析<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2024.02.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1225 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】This study aims to investigate the gene mutation profile in cerebrospinal fluid (CSF)/blood-derived samples from patients with brain metastases of breast cancer for screening drug-resistant genes to verify their resistance mechanisms. 【Methods】A total of 70 patients with brain metastases from breast cancer treated in our hospital were selected for the study. Second-generation sequencing technology was used to detect circulating tumor DNA (ctDNA) in CSF and blood samples to understand the gene mutation status, and to screen drug resistance and analyze the association with mutant genes. 【Results】The main gene mutations detected in the 70 patients included TP53, HER2, PIK3CA, BRCA1, and BRCA2. The mutation detection rate in CSF-derived samples was 100% (70/70), which was higher than 65.71% (46/70) in blood-derived samples (P<0.05). Compared to 21 samples without HER2 and PIK3CA mutations (considering as the control group), patients with HER2 mutations showed higher resistance to trastuzumab (P<0.05). Patients with PIK3CA mutations did not show statistically significant differences in resistance to trastuzumab, atezolizumab, paclitaxel, and doxorubicin, if compared to the control group (P<0.05). Similarly, the resistance of HER2 mutation patients to atezolizumab, paclitaxel, and doxorubicin was not significantly different from that of the control group (P<0.05). 【Conclusion】CSF in patients with breast cancer brain metastases can more accurately reflect possible brain metastasis status in comparison to the blood. The detection of HER2 mutations suggests the presence of corresponding drug resistance, which is of significant importance for medication guidance and monitoring of drug resistance.

Key words： Breast Neoplasms/GE Neoplasm Metastasis Genes Drug Tolerance

Received: 10 October 2023

PACS:

R737.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Mei
	TAN Yue
	LI Gang
	et al

Cite this article:

YANG Mei,TAN Yue,LI Gang, et al. Identification and Functional Verification of Drug-Resistant Gene Mutations Associated with Breast Cancer Brain Metastasis Based on Cerebrospinal Fluid and Blood Samples[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 171-173.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.02.004 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I2/171

[1] 张茜敏,庄璐璐,黄嵘. 乳腺癌脑转移机制、诊疗及预后的研究[J].医学信息,2023,36(3):185-188.
[2] 李之薇,何昕珈,杨林青,等. 血液循环肿瘤DNA在子宫颈癌中的研究进展[J].肿瘤研究与临床,2023,35(7):552-556.
[3] 肖梦加,欧阳取长,胡哲煜,等. 循环肿瘤DNA在晚期乳腺癌的临床应用进展[J].临床肿瘤学杂志,2018,23(9):855-860.
[4] 严婕,何建怀,胡雄强. 曲妥珠单抗、吉西他滨、紫杉醇联合疗法对转移性乳腺癌患者血清肿瘤标志物和免疫功能的影响[J].实用癌症杂志,2019,34(6):919-922.
[5] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609.
[6] 刘福成,万智毅,杨盈赤. 基于循环肿瘤DNA的微小残留病灶检测在结直肠癌预后中的应用进展[J].癌症进展,2023,21(4):370-374.
[7] 马玉红,刘永瑛,赵良玉,等. 外周血ctDNA在结直肠癌中的临床筛查研究[J].宁夏医学杂志,2022,44(5):392-395.
[8] 齐艳梅,李瑞杰,汪领. 外周血ctDNA及Survivin预测NSCLC预后的临床研究[J].临床肺科杂志,2022,27(1):83.
[9] 朱立才,李明娟,王英,等. ctDNA对TKI靶向治疗EGFR突变型肺腺癌疗效及预后的预测价值[J].临床肺科杂志,2021,26(4):562-566.
[10] 陈欣彤. 脑脊液ctDNA活检在髓母细胞瘤的研究进展[J].检验医学与临床,2023,20(15):2256-2259.
[11] 商宏伟,马光耀,孙盛斌. 肺癌脑转移患者脑脊液ctDNA样本EGFR-T790M突变分析[J].临床肿瘤学杂志,2018,23(10):959-960.
[12] 韦光楠,廖宁,陈博. HER2阳性乳腺癌ERBB3基因E928G点突变功能的初步研究[J].医学综述,2022,28(7):1441.
[13] 王雅君,赵燕南,王碧芸. 抗HER2靶向药物治疗HER2阳性乳腺癌脑转移的研究进展[J].复旦学报(医学版),2023,50(1):140-146.
[14] 李彬,张桂芳,周林静,等. 三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J].国际肿瘤学杂志,2023,50(5):263-267.
[15] 潘佳妮,曹文明. BRCA1/2突变乳腺癌PARP抑制剂治疗及回复突变研究进展[J].实用肿瘤杂志,2023,38(1):86-95.